Overview

Tech Summary

Promoter Holding

Posts

ERIS

601234567892012345678990123456789.2012345678950123456789
+4.80 (+0.77%)
The current prices are delayed.Login/Sign Up to see live prices.
Previous Close: 624.45
1D
5D
1M
3M
1Y
5Y
Today's low
616.25
Today's high
650.95
52 week low
600.3
52 week high
774
Volume
73746
About
Tech Summary
DMA(12)
₹673.23
DMA(50)
₹705.3
DMA(100)
₹695.66
DMA(200)
₹688.76
Fund Summary
Market Cap
₹8557.8 Cr.
Enterprise Value
₹8519.53 Cr.
No. of Shares
13.6
P/E
21.07
RoE
24.78
Debt/Equity
0
Valuations
PE Chart
21.022.023.024.0
PB Chart
4.64.85.05.2
Promoter Holdings
Public : 23.52%
FII : 13.31%
DII : 10.5%
Promoter : 52.66%
Others : 0%
Charts
Debt/Equity
0.000.100.200.300.40
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
ROE vs ROCE
2530354045
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
ROE
ROCE
Revenue vs Profitability (1000Cr.)
0.40.60.81.01.2
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
Revenue
Profit
Margins(%)
25303540
Mar, 2018Mar, 2019Mar, 2020Mar, 2021
Net Margin
Gross Margin
About
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Stock Sentiments
100% Bullish
0% Bearish
2 live trades of Rs. 65,679
F
faisalkannathupara
 
Reputation: 0 • 
Today 4:01 PM
ERIS
100 Qty (B) New Trade
jitendrakumar789
 
Reputation: 0 • 
Jan 24 5:36 PM
ERIS
50 Qty (S) Exited₹0
Posts by FrontPage Users
Add a comment
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 18 11:43 PM
Buy Eris Lifesciences; target of Rs 780: Motilal Oswal
Buy Eris Lifesciences; target of Rs 780: Motilal Oswal
Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 780 in its research report dated January 18, 2023.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 18 9:03 PM
Eris Lifesciences falls as margins contract; derma brands' acquisition fails to cheer Street
Eris Lifesciences falls as margins contract; derma brands' acquisition fails to cheer Street
Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 18 6:36 PM
Buy Eris Lifesciences, target price Rs 780:  Motilal Oswal Financial Services
Buy Eris Lifesciences, target price Rs 780: Motilal Oswal Financial Services
Eris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 18 5:13 PM
Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher
Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated January 18, 2023.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 18 1:26 AM
India's Eris Lifesciences to buy some dermatology brands from Glenmark Pharma
India's Eris Lifesciences to buy some dermatology brands from Glenmark Pharma
The deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction is expected to achieve financial closure very soon, Eris said
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 17 7:53 PM
Eris Lifesciences Q3 PAT seen up 7.2% YoY to Rs 1,080 cr: Nirmal Bang
Eris Lifesciences Q3 PAT seen up 7.2% YoY to Rs 1,080 cr: Nirmal Bang
Net Sales are expected to increase by 37 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 4,549 crore, according to Nirmal Bang.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 13 3:26 PM
Rs 6,000 crore bonanza! These 3 index heavyweights topped MFs’ shopping list in December
Rs 6,000 crore bonanza! These 3 index heavyweights topped MFs’ shopping list in December
Shares of HCL Technologies dropped sharply in December by more than 7%, after the company trimmed its revenue growth guidance for the current financial year, citing that higher-than-expected furloughs will affect growth in the second half of the year.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Dec 23, 2022 2:36 PM
Should  you book profits or buy on dips now? Dipan Mehta explains
Should you book profits or buy on dips now? Dipan Mehta explains
“A better way to play pharma would be through hospital stocks. Then we also have these domestic-oriented pharma companies like JB Chemicals or Eris Lifesciences and then the pharma MNCs. Those also are a secular growth story at this point of time because spending on medicine is going to keep on increasing as healthcare possibilities expand.”
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Oct 27, 2022 9:36 PM
What is the real risk factor for the Reliance stock? Dipan Mehta answers
What is the real risk factor for the Reliance stock? Dipan Mehta answers
“The way Apollo has strategised the capital allocation policy and the value which they are creating in digital business is impressive. I would go with that company. Of course, there are other plays as well but when you like a sector, you go for the market leader and that generally works out pretty well.”
The Economic Times
1 Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Oct 25, 2022 8:13 PM
Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher
Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated October 25, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
Profit Picks-display-image
Reputation: 676  •  Oct 18, 2022 5:51 PM

Head and shoulders Pattern
Resistance range again going to test
If breakout go for buying #ERIS
Chartbusters - chart - 14241871
1 Like
Comment
Share
Add a comment
Vv Stock Zone-display-image
Reputation: 56  •  Oct 17, 2022 8:03 PM

#ERIS bought positional at 735
Sl 715
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Oct 3, 2022 4:16 PM
Golden Crossovers: These 3 stocks signal further bullishness
Golden Crossovers: These 3 stocks signal further bullishness
It occurs when the short-term moving average crosses over the major long-term moving average on the upside. These stocks' 50-day simple moving averages (SMA) crossed their 200-day SMAs on September 29.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Sep 3, 2022 1:41 AM
Watch out! Adani Green, ONGC among 46 NSE stocks making bearish crossovers
Watch out! Adani Green, ONGC among 46 NSE stocks making bearish crossovers
Stocks such as Shree Cement, Wonderla Holidays, Jyothy Labs, Phoenix Mills, Prataap Snacks and Eris Lifesciences are showing bearish trends on the MACD indicator.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Sep 1, 2022 5:16 PM
Buy Eris Lifesciences, target price Rs 825:  Prabhudas Lilladher
Buy Eris Lifesciences, target price Rs 825: Prabhudas Lilladher
Eris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 9395.71 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Aug 25, 2022 5:41 AM
Eris Lifesciences Scouting for Acquisitions to Diversify Biz
Eris Lifesciences Scouting for Acquisitions to Diversify Biz
Through acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry segments, followed by another acquisition in 2019 of anti-diabetes brand Zomelis, generic version of Vildagliptin, from Novartis, which became a ₹100 crore brand for the company. Earlier this year, the company bought Oaknet for ₹650 crore. Eris Lifesciences ended 2021-22 with revenues of ₹1,347 crore, with 53% contributed by cardiology and anti-diabetes medications.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Aug 9, 2022 4:33 PM
Buy Eris Lifesciences; target of Rs 825: Prabhudas Lilladher
Buy Eris Lifesciences; target of Rs 825: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 825 in its research report dated August 08, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Aug 6, 2022 1:21 AM
Eris Lifesciences enters licensing deal with Biocon for insulin glargine
Eris Lifesciences enters licensing deal with Biocon for insulin glargine
The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its revenues from cardio-metabolic therapeutic segment, and has adopted a “Full Service” approach to diabetes management with a comprehensive range of oral anti-diabetics, insulins, and glucose testing devices.
The Economic Times
Like
Comment
Share
Add a comment
V Trade Point-display-image
Reputation: 1,638  •  Jul 25, 2022 2:44 PM
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jul 8, 2022 11:03 PM
Eris Lifesciences Q1 PAT seen up 4.3% YoY to Rs 111.3 cr: Prabhudas Lilladher
Eris Lifesciences Q1 PAT seen up 4.3% YoY to Rs 111.3 cr: Prabhudas Lilladher
Net Sales are expected to increase by 9.1 percent Y-o-Y (up 24.6 percent Q-o-Q) to Rs 381.1 crore, according to Prabhudas Lilladher.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jul 8, 2022 3:21 PM
Buy Eris Lifesciences, target price Rs 850:  Prabhudas Lilladher
Buy Eris Lifesciences, target price Rs 850: Prabhudas Lilladher
Eris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8921.10 Crore) operating in Pharmaceuticals sector.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jun 23, 2022 5:56 PM
Dipan Mehta on one thing that works in market now & where to get it
Dipan Mehta on one thing that works in market now & where to get it
“Only three things work in the market; growth, growth and growth. That is all. We are chasing that and at this point of time, growth is available at reasonable valuation. It is a simple mantra one can follow and one cannot go wrong over there. ”
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jun 16, 2022 3:31 PM
Not the time for cowboy antics, take defensive positions and create as much cash as possible: Dipan Mehta
Not the time for cowboy antics, take defensive positions and create as much cash as possible: Dipan Mehta
“There is no visibility of a timeline as to when the current crisis around inflation and the Ukraine war will end. There are too many unanswered questions and in such times, it is better to not to have a cowboy attitude and just be on the safer side and take defensive positions and create as much cash as and when you have an opportunity to do so.”
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jun 8, 2022 2:26 AM
Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drug
Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drug
BI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing or exporting in any form in India either by themselves or through their directors, partners licenses, stockist and distributors, agents etc., jointly and severally until the next date of hearing.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jun 1, 2022 3:41 AM
Ahead of Market: 12 things that will decide D-Street action on Wednesday
Ahead of Market: 12 things that will decide D-Street action on Wednesday
AIA Engineering, Fine Organic, Timken India, CreditAccess Grameen, M&M, Pheonix Mills and HAL witnessed strong buying interest from market participants as they scaled their fresh 52-week highs, signalling bullish sentiment.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  May 18, 2022 1:43 AM
Buy Eris Lifesciences; target of Rs 870: Motilal Oswal
Buy Eris Lifesciences; target of Rs 870: Motilal Oswal
Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 870 in its research report dated May 16, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  May 7, 2022 7:18 PM
Buy Eris Lifesciences; target of Rs 870: Motilal Oswal
Buy Eris Lifesciences; target of Rs 870: Motilal Oswal
Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 870 in its research report dated May 05, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  May 7, 2022 3:33 PM
Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher
Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated May 05, 2022.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  May 4, 2022 6:51 PM
Eris acquires Oaknet Healthcare for Rs 650 crore to gain foothold in derma segment
Eris acquires Oaknet Healthcare for Rs 650 crore to gain foothold in derma segment
The drug maker said the acquisition will be completed by way of a share purchase agreement as a result of which Oaknet will become a wholly owned subsidiary of Eris.
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  May 4, 2022 5:38 PM
Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore
Eris Lifesciences acquires Oaknet Healthcare for Rs 650 crore
The acquisition will be completed by way of a share purchase agreement and accordingly Oaknet will become a wholly-owned subsidiary of Eris, the drug firm said in a statement.
Moneycontrol
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  May 3, 2022 8:51 PM
Eris Lifesciences Q4 Results: Net profit rises 17% to Rs 80 crore
Eris Lifesciences Q4 Results: Net profit rises 17% to Rs 80 crore
On the outlook, Eris Lifesciences said it has an exciting pipeline of 'patent expiration' opportunities coming up in the cardiometabolic segment over the next three to four years.
The Economic Times
Like
Comment
Share
Add a comment
ResultsBot-display-image
Reputation: 20,269  •  May 2, 2022 12:30 AM

#ERIS will declare results on May 3, 2022
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Apr 14, 2022 10:38 PM
Eris Lifesciences Q4 PAT seen up 30.7% YoY to Rs 89.2 cr: Prabhudas Lilladher
Eris Lifesciences Q4 PAT seen up 30.7% YoY to Rs 89.2 cr: Prabhudas Lilladher
Net Sales are expected to increase by 12.2 percent Y-o-Y (down 6.1 percent Q-o-Q) to Rs 312.1 crore, according to Prabhudas Lilladher.
Moneycontrol
Like
Comment
Share
Add a comment
Finvest Guruji-display-image
Reputation: 6,233  •  Mar 15, 2022 2:57 PM
FINVESTGURUJI in ERIS
**BUYING ERIS ABOVE 727** FOR TG 733/745/755/76...

🔥 **Bravoooo guys breakout in eris and blasted up **
727 to 748
Like
Comment
Share
Add a comment
Finvest Guruji-display-image
Reputation: 6,233  •  Mar 15, 2022 2:50 PM

**BUYING ERIS ABOVE 727**
FOR TG 733/745/755/765
WITH SL OF 718
Like
Comment
Share
Add a comment
Spoiledbrahmin-display-image
Reputation: 1,182  •  Jan 29, 2022 2:44 PM

#ERIS : Q3 CONS NET PROFIT RUPEES 1B VS 902M (YOY)
Q3 EBITDA 1.2B RUPEES VS 1.1B (YOY) ||
Q3 EBITDA MARGIN 36.64% VS 34.54% (YOY)
BEATS YOY
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Jan 28, 2022 11:31 PM
Eris Lifesciences Q3 Results: Profit rises to Rs 101 crore
Eris Lifesciences Q3 Results: Profit rises to Rs 101 crore
Revenue stood at Rs 332 crore in the third quarter of the current fiscal as compared to Rs 310 crore in the year-ago period, Eris Lifesciences said in a statement.
The Economic Times
Like
Comment
Share
Add a comment
Harry-display-image
Reputation: 1,825  •  Jan 28, 2022 8:38 PM

*Eris Lifesciences Ltd.* | *CMP* Rs. 713 | *M Cap* Rs. 9694 Cr | *52 W H/L* 863/474
(Nirmal Bang Retail Research)
*Result is ok*
Revenue from Operations came at Rs. 332.2 Cr (-7.6% QoQ, 7% YoY) vs QoQ Rs. 359.7 Cr, YoY Rs. 310.4 Cr
EBIDTA came at Rs. 121.7 Cr (-12.9% QoQ, 13.5% Y......read more
1 Like
Comment
Share
Add a comment
ResultsBot-display-image
Reputation: 20,269  •  Jan 27, 2022 12:30 AM

#ERIS will declare results on Jan 28, 2022
Do you have any view on the results? Let's aggregate whatever information we have from other sources for everyone's benefit.
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Dec 29, 2021 10:06 PM
CY22 to be year of mid & smallcaps? 3 deep value ideas from G Chokkalingam
CY22 to be year of mid & smallcaps? 3 deep value ideas from G Chokkalingam
"I am extremely bullish on the economy as the Tsunami of retail investors gives me a lot of confidence that CY2022 is going to be the year of small and midcaps."
The Economic Times
Like
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 29,687  •  Dec 28, 2021 10:26 PM
Market Movers: Resurgent Covid brings tailwinds for healthcare stocks
Market Movers: Resurgent Covid brings tailwinds for healthcare stocks
Shares of healthcare stocks – pharma companies and diagnostic companies – jumped in trade today as the government got into battle mode to stem the spread of the Omicron variant.
The Economic Times
Like
Comment
Share
Add a comment
ReportBot-display-image
Reputation: 39,809  •  Dec 28, 2021 6:30 PM

Motilal Oswal target on ERIS
Date: 27-Dec-21 Broker: Motilal Oswal Price @ Call: 685 Target: 870 Potential: 27.01% Recommendation: BUY
3 Likes
Comment
Share
Add a comment
Load More Posts